Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01938482




Registration number
NCT01938482
Ethics application status
Date submitted
5/09/2013
Date registered
10/09/2013
Date last updated
9/05/2017

Titles & IDs
Public title
Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029
Scientific title
A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects
Secondary ID [1] 0 0
117226
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acne Vulgaris 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - 0.3% GSK1940029 gel
Treatment: Drugs - 1% GSK1940029 gel
Treatment: Drugs - 0.3%/1% vehicle gel only

Experimental: Part 1 - Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as a single App 24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts

Experimental: Part 2 - Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts


Treatment: Drugs: 0.3% GSK1940029 gel
Will be supplied as gel for topical application

Treatment: Drugs: 1% GSK1940029 gel
Will be supplied as gel for topical application

Treatment: Drugs: 0.3%/1% vehicle gel only
Will be supplied as gel for topical application
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety of GSK1940029 as assessed by physical examination findings.
Timepoint [1] 0 0
Screening, Day -1, and follow-up (FU) (Days 6 to 8) of Part 1; Screening, Day -1, and FU (Days 20 to 22) of Part 2
Primary outcome [2] 0 0
Safety of GSK1940029 as assessed by vital signs
Timepoint [2] 0 0
Screening, Days 1, 2 and FU (Days 6 to 8) of Part 1; Screening, Days 1, 2, 7 14, and FU (Days 20 to 22) of Part 2
Primary outcome [3] 0 0
Safety of GSK1940029 as assessed by 12-lead electrocardiogram (ECG)
Timepoint [3] 0 0
Screening, Day 1 and Day 2 of Part 1; Screening, Day 1, 2, 7, 12, 13 and 14 of Part 2
Primary outcome [4] 0 0
Safety of GSK1940029 as assessed by dual lead telemetry
Timepoint [4] 0 0
Pre-dose through 4h post-dose on Day 1 of Part 1 and Part 2
Primary outcome [5] 0 0
Safety of GSK1940029 as assessed by hematology and chemistry parameters of clinical laboratory test
Timepoint [5] 0 0
Screening, Days 1, 2 and FU (Days 6 to 8) of Part 1; Screening, Days 1, 4, 7, 14, and FU (Days 20 to 22) of Part 2
Primary outcome [6] 0 0
Safety of GSK1940029 as assessed by urinalysis parameters of clinical laboratory test
Timepoint [6] 0 0
Screening, Days -1, 1, 2 and FU (Days 6 to 8) of Part 1; Screening, Days -1, 1, 2, 4, 7, 14, , and FU (Days 20 to 22) of Part 2
Primary outcome [7] 0 0
Safety of GSK1940029 as assessed by urine albumin:creatinine ratio (ACR)
Timepoint [7] 0 0
Days -1, 1, 2 and FU (Days 6 to 8) of Part 1; Days -1, 1, 2, 4, 7, 14 and FU (Days 20 to 22) of Part 2
Primary outcome [8] 0 0
Safety of GSK1940029 as assessed by adverse events
Timepoint [8] 0 0
Day -1 to FU (Days 6-8)of Part 1; Day -1 to FU (Day 20 - 22) of Part 2
Secondary outcome [1] 0 0
Plasma GSK1940029 pharmacokinetics (PK)
Timepoint [1] 0 0
Part1: 1h, 2h, 4h, 6h, 8h, 12h, 16h, 22.5h, 24h and 36h post-dose. Part 2: 1h, 2h, 4h, 6h, 8h, 12h, 16h and 22.5h post-Day 1 dose; Pre-dose on Days 2, 12 and 13; and 1h, 2h, 4h, 6h, 8h, 12h, 16h, 22.5h and 22.5-24h post-Day 14 dose
Secondary outcome [2] 0 0
Ocular tolerability of topical applications of GSK1940029
Timepoint [2] 0 0
Screening, Days -1, 1, 2 and FU (Days 6 to 8) of Part 1; Screening, Days -1, 7, 14 and FU (Days 20 to 22) of Part 2

Eligibility
Key inclusion criteria
- Healthy as determined by a responsible and experienced physician, based on a medical
evaluation including medical history, physical examination, laboratory tests and
cardiac monitoring.

- A subject with a clinical abnormality or laboratory parameters outside the reference
range for the population being studied may be included only if the Investigator and
the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to
introduce additional risk factors and will not interfere with the study procedures.

- Male or female between 18 and 65 years of age inclusive, at the time of signing the
informed consent.

- A female subject is eligible to participate if she is of:

- Non-childbearing potential defined as pre-menopausal females with a documented tubal
ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous
amenorrhea (in questionable cases a blood sample with simultaneous follicle
stimulating hormone [FSH] >40 milli international units MIU/ milliliter (mL) and
estradiol < 40 picograms (pg)/mL (<147 picomole [pmol]/liter [L]) is confirmatory).
Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt
will not be allowed.

- Male subjects with female partners of child-bearing potential must agree to use one of
the contraception methods listed in the Protocol. This criterion must be followed from
the time of the first dose of study medication until after study follow-up visit.

- Alanine amino transfrase, alkaline phosphatase and bilirubin <=1.5 x ULN (upper limit
of normal) (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated
and direct bilirubin <35%).

- Based on single or averaged assessments, corrected QT interval (QTc) < 450
milliseconds (msec); or QTc <480 msec in subjects with Bundle Branch Block.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of screening

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome). Subjects with a history of gall stones,
asymptomatic gallstones or cholecystectomy will be excluded.

- A positive pre-study drug/alcohol screen.

- A positive test for Human Immunodeficiency virus HIV antibody.

- History of regular alcohol consumption within 6 months of the study defined as: an
average weekly intake of >14 standard drinks. One standard drink is equivalent to 10
gram of alcohol: 285 mL of beer, 100 mL of wine or 30 mL of 40% alcohol by volume
distilled spirits.

- History of or current meibomian gland dysfunction or dry eye disease

- History or presence of significant skin disorder (such as but not limited to severe
(extensive) atopic dermatitis, severe eczema, psoriasis or skin cancer) that would in
any way confound interpretation of the study results, or subjects who present with
damaged skin including sunburn, moles, uneven skin tones, scar tissue, tattoos, body
piercings, sunburn, branding or other disfiguration on or near the intended site of
application which could interfere with the grading.

- History of cutaneous photodisorder, such as photoallergic reaction or polymorphic
light eruption. - History of cold urticaria and reactions to extreme temperatures.

- History of allergy to soaps, lotions, cosmetics, tape/adhesives, petrolatum or latex
or topical drugs of same class as the study medication.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or GSK
Medical Monitor, contraindicates their participation.

- History of sensitivity to heparin or heparin-induced thrombocytopenia.

- History of severe, chronic asthma or significant allergies (including food, drug or
cutaneous allergies). Subjects with the presence or a history of atopy (seasonal
allergies, allergic rhinitis) or mild (limited) eczema will be allowed to participate
in the study, although applications at sites with active eczema will not be allowed.

- Use of topical medications such as but not limited to retinoids, steroids, and
transdermal hormone replacement therapies on or near the intended site of application
within 8 weeks prior to dosing through treatment follow up. Use of other topical
preparations such as those containing vitamins, supplements or herbal within 2 weeks
prior to dosing through treatment follow up.

- Unable to refrain from the use of topical medications from the initial dose of study
medication through follow-up.

- Foreseeable intensive ultraviolet (UV) exposure during the study (solar or artificial)
as follows: subjects must not be exposed to direct sunlight for sun tanning or exposed
to skin tanning devices (e.g. sunbed) for the duration of the study.

- Participation in any patch test for cumulative irritation or sensitization within 4
weeks preceding the first dose of study medication.

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Unable to refrain from the use of prescription or non-prescription drugs, including
vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or
14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is
longer) prior to the first dose of study medication, unless in the opinion of the
Investigator and GSK Medical Monitor the medication will not interfere with the study
procedures or compromise subject safety.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.

- Unwillingness or inability to follow the procedures outlined in the protocol.

- Subject is mentally or legally incapacitated.

- Unable to refrain from consumption of red wine, seville oranges, grapefruit or
grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit
juices from 7 days prior to the first dose of study medication

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/10/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/02/2015
Sample size
Target
Accrual to date
Final
55
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
GSK Investigational Site - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The proposed indication for GSK1940029 is topical treatment of acne, the early clinical plan
will evaluate the irritation potential of GSK1940029 (Study SCD117225 - 3 Part study); and
safety, tolerability and pharmacokinetics of GSK1940029 (Study SCD117226 - 2 Part study),
after topical administration on healthy subjects and acne patients. Study SCD117226 will be a
randomized, single-blind, dose-rising study to evaluate the safety, tolerability and
preliminary pharmacokinetics of single and 14 day repeat topical applications of GSK1940029
gel on the intact skin of healthy human subjects. Part 1: (single-dose) subjects will receive
0.3% or 1% GSK1940029 (or matching vehicle), as a single approximately (App) 24 hour (h)
(22.5h) application to a surface area of 400 square centimeter (cm^2) (0.3%), 400 cm^2 (1%)
or 1200 cm^2 (1%), respectively, in each of three sequential cohorts. Part 2: (repeat-dose)
subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h)
application to a surface area of 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%),
respectively, in each of three sequential cohorts. Parts within Study SCD117225 and Study
SCD117226 will have interdependencies. No significant primary irritation signal in Study
SCD117225 Part 1 (primary irritation) would allow initiation of Study SCD117226 Part 1. Once
safety, tolerability and exposure information are determined in Study SCD117226 Part 1, then
Part 2 (cumulative irritation) of Study SCD117225 may be initiated along with Part 2 of Study
SCD117226. No significant cumulative irritation signal (study SCD117225 Part 2) in
combination with adequate 14-day safety (study SCD117226 Part 2) would allow initiation of
Part 3 (facial irritation) of Study SCD117225.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01938482
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01938482